UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Browse by UCL Departments and Centres

Group by: Author | Type
Jump to: A | B | C | D | E | F | G | H | J | K | L | M | O | P | Q | R | T | V | W
Number of items: 70.

A

Ainley, L; Chavda, SJ; Counsell, N; Cheesman, S; Newrick, F; Horder, J; Kyriakou, C; ... Yong, K; + view all (2021) DT‐PACE/ESHAP chemotherapy regimens as salvage therapy for multiple myeloma prior to autologous stem cell transplantation. British Journal of Haematology , 192 (3) e73-e77. 10.1111/bjh.17248. Green open access
file

Arend, RC; Monk, BJ; Herzog, TJ; Moore, KN; Shapira-Frommer, R; Ledermann, JA; Tewari, KS; ... Penson, RT; + view all (2021) Utilizing an interim futility analysis of the OVAL study (VB-111-701/GOG 3018) for potential reduction of risk: A phase III, double blind, randomized controlled trial of ofranergene obadenovec (VB-111) and weekly paclitaxel in patients with platinum resistant ovarian cancer. Gynecologic Oncology , 161 (2) pp. 496-501. 10.1016/j.ygyno.2021.02.014. Green open access
file

Au, L; Hatipoglu, E; Robert de Massy, M; Litchfield, K; Beattie, G; Rowan, A; Schnidrig, D; ... TRACERx Renal Consortium; + view all (2021) Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma. Cancer Cell , 39 pp. 1497-1518. 10.1016/j.ccell.2021.10.001. Green open access
file

B

Bachy, E; Rufibach, K; Parreira, J; Launonen, A; Nielsen, T; Hackshaw, A; (2021) Phase III Clinical Trials in First-Line Follicular Lymphoma: A Review of Their Design and Interpretation. Advances in Therapy 10.1007/s12325-021-01738-2. (In press). Green open access
file

Baert, T; Ferrero, A; Sehouli, J; O Donnell, DM; González-Martín, A; Joly, F; Van der Velden, J; ... Ledermann, JA; + view all (2021) The systemic treatment of recurrent ovarian cancer revisited. Annals of Oncology , 32 (6) pp. 710-725. 10.1016/j.annonc.2021.02.015. Green open access
file

Balestrini, S; Koepp, MJ; Gandhi, S; Rickman, HM; Yen Shin, G; Houlihan, CF; Anders-Cannon, J; ... Sisodiya, SM; + view all (2021) Clinical outcomes of COVID-19 in long-term care facilities for people with epilepsy. Epilepsy & Behavior , 115 , Article 107602. 10.1016/j.yebeh.2020.107602. Green open access
file

Bentham, R; Litchfield, K; Watkins, TBK; Lim, EL; Rosenthal, R; Martinez-Ruiz, C; Hiley, CT; ... McGranahan, N; + view all (2021) Using DNA sequencing data to quantify T cell fraction and therapy response. Nature , 597 pp. 555-560. 10.1038/s41586-021-03894-5. Green open access
file

Biasco, L; Izotova, N; Rivat, C; Ghorashian, S; Richardson, R; Guvenel, A; Hough, R; ... Amrolia, PJ; + view all (2021) Clonal expansion of T memory stem cells determines early anti-leukemic responses and long-term CAR T cell persistence in patients. Nature Cancer , 2 pp. 629-64. 10.1038/s43018-021-00207-7. Green open access
file

C

Camilleri, M; Sive, J; Wilson, W; Pang, G; Jenner, R; Phillips, E; Popat, R; ... Yong, K; + view all (2021) COVID-19 and myeloma clinical research - experience from the CARDAMON clinical trial. British Journal of Haematology , 192 (1) E14-E16. 10.1111/bjh.17168. Green open access
file

Camilleri, M; Cuadrado, M; Phillips, E; Wilson, W; Jenner, R; Pang, G; Kamora, S; ... Yong, K; + view all (2021) Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study. British Journal of Haematology 10.1111/bjh.17377. (In press). Green open access
file

Chan, WY; Counsell, N; de Tute, R; De-Silva, D; Phillips, EH; Cavenagh, J; Adedayo, T; ... Yong, KL; + view all (2021) Outcomes of relapse in patients with deferred autologous stem cell transplant after achieving at least very good partial response following bortezomib, adriamycin, dexamethasone chemotherapy for newly diagnosed multiple myeloma in the phase II PADIMAC trial. British Journal of Haematology 10.1111/bjh.17903. (In press).

Clamp, AR; Lorusso, D; Oza, AM; Aghajanian, C; Oaknin, A; Dean, A; Colombo, N; ... Ledermann, JA; + view all (2021) Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3. International Journal of Gynecological Cancer 10.1136/ijgc-2020-002240. (In press). Green open access
file

Clark, JJ; Dwyer, D; Pinwill, N; Clark, P; Johnson, P; Hackshaw, A; (2021) The effect of clinical decision making for initiation of systemic anticancer treatments in response to the COVID-19 pandemic in England: a retrospective analysis. The Lancet Oncology , 22 (1) pp. 66-73. 10.1016/S1470-2045(20)30619-7. Green open access
file

Colombo, N; Ledermann, JA; (2021) Updated treatment recommendations for newly diagnosed epithelial ovarian carcinoma from the ESMO Clinical Practice Guidelines. Annals of Oncology , 32 (10) pp. 1300-1303. 10.1016/j.annonc.2021.07.004.

Concin, N; Creutzberg, CL; Vergote, I; Cibula, D; Mirza, MR; Marnitz, S; Ledermann, JA; ... Matias-Guiu, X; + view all (2021) ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma. Virchows Archiv , 478 pp. 153-190. 10.1007/s00428-020-03007-z. Green open access
file

Concin, N; Matias-Guiu, X; Vergote, I; Cibula, D; Mirza, MR; Marnitz, S; Ledermann, J; ... Creutzberg, CL; + view all (2021) ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Radiotherapy and Oncology , 154 pp. 327-353. 10.1016/j.radonc.2020.11.018. Green open access
file

Concin, N; Matias-Guiu, X; Vergote, I; Cibula, D; Mirza, MR; Marnitz, S; Ledermann, J; ... Creutzberg, CL; + view all (2021) ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. International Journal Of Gynecological Cancer , 31 (1) pp. 12-39. 10.1136/ijgc-2020-002230. Green open access
file

Cross, AJ; Myles, J; Greliak, P; Hackshaw, A; Halloran, S; Benton, SC; Addison, C; ... Raine, R; + view all (2021) Including a general practice endorsement letter with the testing kit in the Bowel Cancer Screening Programme: Results of a cluster randomised trial. Journal of Medical Screening 10.1177/0969141321997480. Green open access
file

D

Dettorre, GM; Dolly, S; Loizidou, A; Chester, J; Jackson, A; Mukherjee, U; Zambelli, A; ... OnCovid study group; + view all (2021) Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score. Journal for ImmunoTherapy of Cancer , 9 (3) , Article e002277. 10.1136/jitc-2020-002277. Green open access
file

E

Elyashiv, O; Wong, YNS; Ledermann, JA; (2021) Frontline Maintenance Treatment for Ovarian Cancer. Current Oncology Reports , 23 (8) , Article 97. 10.1007/s11912-021-01088-w. Green open access
file

Eyre, TA; Wilson, W; Kirkwood, AA; Wolf, J; Hildyard, C; Plaschkes, H; Griffith, J; ... Hatton, CSR; + view all (2021) Infection-related morbidity and mortality among older patients with DLBCL treated with full- or attenuated-dose R-CHOP. Blood Advances , 5 (8) pp. 2229-2236. 10.1182/bloodadvances.2021004286. Green open access
file

F

Fox, TA; Kirkwood, AA; Enfield, L; O'Reilly, M; Arulogun, S; D'Sa, S; O'Nions, J; ... Morris, EC; + view all (2021) Low seropositivity and suboptimal neutralisation rates in patients fully vaccinated against COVID-19 with B-cell malignancies. British Journal of Haematology 10.1111/bjh.17836.

G

Gleeson, M; Counsell, N; Cunningham, D; Lawrie, A; Clifton-Hadley, L; Hawkes, E; McMillan, A; ... Linch, D; + view all (2021) Prognostic indices in diffuse large B-cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R-CHOP 14 versus 21 phase 3 trial. British Journal of Haematology , 192 (6) pp. 1015-1019. 10.1111/bjh.16691. Green open access
file

H

Hackshaw, A; Berg, CD; (2021) An efficient randomised trial design for multi-cancer screening blood tests: nested enhanced mortality outcomes of screening trial. Lancet Oncology , 22 (10) pp. 1360-1362. 10.1016/S1470-2045(21)00204-7. Green open access
file

Hackshaw, A; Cohen, SS; Reichert, H; Kansal, AR; Chung, KC; Ofman, JJ; (2021) Estimating the population health impact of a multi-cancer early detection genomic blood test to complement existing screening in the US and UK. British Journal of Cancer 10.1038/s41416-021-01498-4. (In press). Green open access
file

Hoskin, P; Popova, B; Schofield, O; Brammer, C; Robinson, M; Brunt, AM; Madhavan, K; ... Kirkwood, AA; + view all (2021) 4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trial. The Lancet Oncology , 22 (3) pp. 332-340. 10.1016/S1470-2045(20)30686-0. Green open access
file

Hughes, J; Gyertson, K; Carballo, L; Plant, H; Sharman, M; Ruane, K; Mendoza-Naranjo, A; ... Fisher, P; + view all (2021) A feasibility trial of acupuncture in cancer patients undergoing radiotherapy treatment. Complementary Therapies in Clinical Practice , 43 , Article 101372. 10.1016/j.ctcp.2021.101372.

J

Javaid, F; Pilotti, C; Camilli, C; Kallenberg, D; Bahou, C; Blackburn, J; R. Baker, J; ... Chudasama, V; + view all (2021) Leucine-rich alpha-2-glycoprotein 1 (LRG1) as a novel ADC target. RSC Chemical Biology , 2 (4) pp. 1206-1220. 10.1039/d1cb00104c. Green open access
file

K

Kurtz, JE; Gebski, V; Sukhin, V; Carey, M; Kong, I; Glasspool, RM; Berek, JS; ... Friedlander, M; + view all (2021) Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIG symptom benefit committee. Gynecologic Oncology , 161 (2) pp. 502-507. 10.1016/j.ygyno.2021.02.018. Green open access
file

Kwan, TT; Oza, AM; Tinker, A; Ray-Coquard, I; Oaknin, A; Aghajanian, C; Lorusso, D; ... Swisher, EM; + view all (2021) Preexisting TP53-Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib. JAMA Oncology 10.1001/jamaoncol.2021.4664.

L

Lacas, B; Carmel, A; Landais, C; Wong, SJ; Licitra, L; Tobias, JS; Burtness, B; ... MACH-NC Collaborative Group; + view all (2021) Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group. Radiotherapy and Oncology , 156 pp. 281-293. 10.1016/j.radonc.2021.01.013. Green open access
file

Laszlo, HE; Seward, E; Ayling, RM; Lake, J; Malhi, A; Stephens, C; Pritchard-Jones, K; ... Machesney, M; + view all (2021) Faecal immunochemical test for patients with 'high-risk' bowel symptoms: a large prospective cohort study and updated literature review. British Journal of Cancer 10.1038/s41416-021-01653-x. (In press). Green open access
file

Leary, A; Tan, D; Ledermann, J; (2021) Immune checkpoint inhibitors in ovarian cancer: where do we stand? Therapeutic Advances in Medical Oncology , 13 10.1177/17588359211039899. Green open access
file

Lechner, M; Liu, J; Counsell, N; Ta, NH; Rocke, J; Anmolsingh, R; Eynon-Lewis, N; ... Philpott, C; + view all (2021) Course of symptoms for loss of sense of smell and taste over time in one thousand forty-one healthcare workers during the Covid-19 pandemic: Our experience. Clinical Otolaryngology , 46 (2) pp. 451-457. 10.1111/coa.13683. Green open access
file

Lechner, M; Takahashi, Y; Turri-Zanoni, M; Liu, J; Counsell, N; Hermsen, M; Kaur, RP; ... Hanna, EY; + view all (2021) Clinical outcomes, Kadish-INSICA staging and therapeutic targeting of somatostatin receptor 2 in olfactory neuroblastoma. European Journal of Cancer 10.1016/j.ejca.2021.09.046. (In press).

Ledermann, JA; Zurawski, B; Raspagliesi, F; De Giorgi, U; Arranz Arija, J; Romeo Marin, M; Lisyanskaya, A; ... Sehouli, J; + view all (2021) Maintenance therapy of patients with recurrent epithelial ovarian carcinoma with the anti-tumor-associated-mucin-1 antibody gatipotuzumab: results from a double-blind, placebo-controlled, randomized, phase II study. ESMO Open , 7 (1) , Article 100311. 10.1016/j.esmoop.2021.100311. Green open access
file

Ledermann, JA; Embleton-Thirsk, AC; Perren, TJ; Jayson, GC; Rustin, GJS; Kaye, SB; Hirte, H; ... ICON6 collaborators, .; + view all (2021) Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial. ESMO Open , 6 (2) , Article 100043. 10.1016/j.esmoop.2020.100043. Green open access
file

Lee, CK; Friedlander, ML; Tjokrowidjaja, A; Ledermann, JA; Coleman, RL; Mirza, MR; Matulonis, UA; ... Scott, CL; + view all (2021) Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis. Cancer 10.1002/cncr.33517. (In press). Green open access
file

M

Mandair, D; Khan, MS; Lopes, A; Furtado O'Mahony, L; Ensell, L; Lowe, H; Hartley, JA; ... Meyer, T; + view all (2021) Prognostic Threshold for Circulating Tumor Cells in Patients With Pancreatic and Midgut Neuroendocrine Tumors. Journal of Clinical Endocrinology and Metabolism , 106 (3) pp. 872-882. 10.1210/clinem/dgaa822. Green open access
file

Martinez-Calle, N; Kirkwood, AA; Lamb, M; Smith, A; Khwaja, J; Manos, K; Shrubsole, C; ... Fox, CP; + view all (2021) Systemic ALCL Treated in Routine Clinical Practice: Outcomes Following First-Line Chemotherapy from a Multicentre Cohort. Advances in Therapy 10.1007/s12325-021-01764-0. Green open access
file

McCulloch, R; Lewis, D; Crosbie, N; Eyre, TA; Bolam, S; Arasaretnam, A; Creasey, T; ... Rule, S; + view all (2021) Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients. British Journal of Haematology 10.1111/bjh.17363. Green open access
file

Mikhaeel, NG; Cunningham, D; Counsell, N; McMillan, A; Radford, JA; Ardeshna, KM; Lawrie, A; ... Barrington, SF; + view all (2021) FDG‐PET/CT after two cycles of R‐CHOP in DLBCL predicts complete remission but has limited value in identifying patients with poor outcome – final result of a UK National Cancer Research Institute prospective study. British Journal of Haematology , 192 (3) pp. 504-513. 10.1111/bjh.16875. Green open access
file

Mitchell, RJ; Kirkwood, AA; Barretta, E; Clifton-Hadley, L; Lawrie, E; Lee, S; Leongamornlert, D; ... Fielding, AK; + view all (2021) IKZF1 alterations are not associated with outcome in 498 adults with B-precursor ALL enrolled in the UKALL14 trial. Blood Advances , 5 (17) pp. 3322-3332. 10.1182/bloodadvances.2021004430. Green open access
file

Monk, BJ; Colombo, N; Oza, AM; Fujiwara, K; Birrer, MJ; Randall, L; Poddubskaya, EV; ... Ledermann, JA; + view all (2021) Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial. The Lancet Oncology , 22 (9) pp. 1275-1289. 10.1016/S1470-2045(21)00342-9. Green open access
file

Moorman, Anthony; Butler, Ellie; Barretta, Emilio; Kirkwood, Amy A; Schwab, Claire; Creasey, Thomas; Leongamornlert, Daniel A; ... Enshaei, Amir; + view all (2021) Prognostic impact of chromosomal abnormalities and copy number alterations in adult B-cell precursor acute lymphoblastic leukaemia: a UKALL14 study. Leukemia 10.1038/s41375-021-01448-2. (In press). Green open access
file

Morgan, RD; McNeish, IA; Cook, AD; James, EC; Lord, R; Dark, G; Glasspool, RM; ... Clamp, AR; + view all (2021) Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. The Lancet Oncology , 22 (2) pp. 277-288. 10.1016/S1470-2045(20)30591-X. Green open access
filefilefilefilefile

O

O'Connor, MN; Kallenberg, DM; Camilli, C; Pilotti, C; Dritsoula, A; Jackstadt, R; Bowers, CE; ... Greenwood, J; + view all (2021) LRG1 destabilizes tumor vessels and restricts immunotherapeutic potency. Med , 2 (11) 1231-1252.e10. 10.1016/j.medj.2021.10.002.

Oaknin, A; Oza, AM; Lorusso, D; Aghajanian, C; Dean, A; Colombo, N; Weberpals, JI; ... Coleman, RL; + view all (2021) Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum-based regimen and disease at baseline on efficacy and safety. Cancer Medicine 10.1002/cam4.4260. (In press). Green open access
file

P

Petit, C; Lacas, B; Pignon, J-P; Le, QT; Grégoire, V; Grau, C; Hackshaw, A; ... MACH-NC and MARCH Collaborative Groups; + view all (2021) Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis. Lancet Oncology , 22 (5) pp. 727-736. 10.1016/S1470-2045(21)00076-0. Green open access
file

Pinato, DJ; Scotti, L; Gennari, A; Colomba-Blameble, E; Dolly, S; Loizidou, A; Chester, J; ... Cortellini, A; + view all (2021) Determinants of enhanced vulnerability to COVID-19 in UK cancer patients: a European Study. European Journal of Cancer 10.1016/j.ejca.2021.03.035. (In press). Green open access
file

Pinato, DJ; Tabernero, J; Bower, M; Scotti, L; Patel, M; Colomba, E; Dolly, S; ... Iglesias, M; + view all (2021) Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study. The Lancet Oncology 10.1016/s1470-2045(21)00573-8. (In press). Green open access
file

Popat, R; Counsell, N; De Tute, R; De-Silva, D; Phillips, EH; Cavenagh, JD; Adedayo, T; ... Yong, K; + view all (2021) Using depth of response to stratify patients to front line Autologous Stem Cell Transplant: results of the phase II PADIMAC Myeloma Trial. British Journal of Haematology , 193 (3) e19-e22. 10.1111/bjh.17391. Green open access
file

Post, CCB; De Boer, SM; Powell, ME; Mileshkin, L; Katsaros, D; Bessette, P; Haie-Meder, C; ... Creutzberg, CL; + view all (2021) Long-Term Toxicity and Health-Related Quality of Life After Adjuvant Chemoradiation Therapy or Radiation Therapy Alone for High-Risk Endometrial Cancer in the Randomized PORTEC-3 Trial. International Journal of Radiation Oncology - Biology - Physics , 109 (4) pp. 975-986. 10.1016/j.ijrobp.2020.10.030. Green open access
file

Poveda, A; Floquet, A; Ledermann, JA; Asher, R; Penson, RT; Oza, AM; Korach, J; ... SOLO2/ENGOT-Ov21 investigators, .; + view all (2021) Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet Oncology , 22 (5) pp. 620-631. 10.1016/S1470-2045(21)00073-5. Green open access
filefile

Pujade-Lauraine, E; Fujiwara, K; Ledermann, JA; Oza, AM; Kristeleit, R; Ray-Coquard, I-L; Richardson, GE; ... Monk, BJ; + view all (2021) Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study. The Lancet Oncology , 22 (7) pp. 1034-1046. 10.1016/S1470-2045(21)00216-3. Green open access
file

Pujade-Lauraine, Eric; Fujiwara, Keiichi; Ledermann, Jonathan A; Oza, Amit M; Kristeleit, Rebecca; Ray-Coquard, Isabelle-Laure; Richardson, Gary E; ... Monk, Bradley J; + view all (2021) Avelumab Alone or in Combination With Chemotherapy Versus Chemotherapy Alone in Platinum-Resistant or Platinum-Refractory Ovarian Cancer (JAVELIN Ovarian 200): An Open-Label, Three-Arm, Randomised, Phase 3 Study. Obstetrical & Gynecological Survey , 76 (11) pp. 673-675. 10.1097/OGX.0000000000000980.

Q

Quaife, SL; Waller, J; Dickson, JL; Brain, KE; Kurtidu, C; McCabe, J; Hackshaw, A; ... Janes, SM; + view all (2021) Psychological Targets for Lung Cancer Screening Uptake: A Prospective Longitudinal Cohort Study. Journal of Thoracic Oncology 10.1016/j.jtho.2021.07.025. (In press).

R

Rockall, AG; Barwick, TD; Wilson, W; Singh, N; Bharwani, N; Sohaib, A; Nobbenhuis, M; ... Study Group, M; + view all (2021) Diagnostic accuracy of FET-PET/CT, FDG-PET/CT and diffusion-weighted MRI in detection of nodal metastases in surgically treated endometrial and cervical carcinoma. Clinical Cancer Research 10.1158/1078-0432.ccr-21-1834. (In press). Green open access
file

Roddie, C; Dias, J; O'Reilly, MA; Abbasian, M; Cadinanos-Garai, A; Vispute, K; Bosshard-Carter, L; ... Peggs, KS; + view all (2021) Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia. Journal of Clinical Oncology 10.1200/jco.21.00917. (In press). Green open access
file

Russell, J; Collins, A; Fowler, A; Karanth, M; Saha, C; Docherty, S; Padayatty, J; ... Follows, GA; + view all (2021) Advanced Hodgkin lymphoma in the East of England: a 10-year comparative analysis of outcomes for real-world patients treated with ABVD or escalated-BEACOPP, aged less than 60 years, compared with 5-year extended follow-up from the RATHL trial. Annals of Hematology , 100 pp. 1049-1058. 10.1007/s00277-021-04460-9. Green open access
file

T

Taylor, A; Sundar, SS; Bowen, R; Clayton, R; Coleridge, S; Fotopoulou, C; Ghaem-Maghami, S; ... Morrison, J; + view all (2021) British Gynaecological Cancer Society recommendations for women with gynecological cancer who received non-standard care during the COVID-19 pandemic. International Journal of Gynecologic Cancer 10.1136/ijgc-2021-002942. (In press). Green open access
file

Tjokrowidjaja, A; Friedlander, M; Lord, SJ; Asher, R; Rodrigues, M; Ledermann, JA; Matulonis, UA; ... Lee, CK; + view all (2021) Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy. European Journal of Cancer , 154 pp. 190-200. 10.1016/j.ejca.2021.06.024.

V

Vivekanandan, S; Fenwick, JD; Counsell, N; Panakis, N; Stuart, R; Higgins, GS; Hawkins, MA; (2021) Associations between cardiac irradiation and survival in patients with non-small cell lung cancer: Validation and new discoveries in an independent dataset. Radiotherapy and Oncology , 165 pp. 119-125. 10.1016/j.radonc.2021.10.016.

W

Wall, EC; Wu, M; Harvey, R; Kelly, G; Warchal, S; Sawyer, C; Daniels, R; ... Bauer, DL; + view all (2021) AZD1222-induced neutralising antibody activity against SARS-CoV-2 Delta VOC. The Lancet 10.1016/S0140-6736(21)01462-8. (In press). Green open access
file

Wall, EC; Wu, M; Harvey, R; Kelly, G; Warchal, S; Sawyer, C; Daniels, R; ... Bauer, DLV; + view all (2021) Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. The Lancet 10.1016/s0140-6736(21)01290-3. (In press). Green open access
file

Watts, C; Ashkan, K; Jenkinson, MD; Price, SJ; Santarius, T; Matys, T; Zhang, TT; ... Counsell, N; + view all (2021) An evaluation of the tolerability and feasibility of combining 5-amino-levulinic acid (5-ala) with bcnu wafers in the surgical management of primary glioblastoma. Cancers , 13 , Article 3241. 10.3390/cancers13133241. Green open access
file

Willis, SE; Winkler, C; Roudier, MP; Baird, T; Marco-Casanova, P; Jones, E; Rowe, P; ... Jones, GN; + view all (2021) Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response. British Journal of Cancer 10.1038/s41416-021-01560-1. Green open access
file

Wong, Yien Ning Sophia; (2021) Identification of urine derived lymphocytes as a non-invasive measure of the tumour immune microenvironment in bladder cancer. Doctoral thesis (Ph.D), UCL (University College London). Green open access
file

Wong, YNS; Sng, CCT; Ottaviani, D; Patel, G; Chowdhury, A; Earnshaw, I; Sinclair, A; ... Lee, AJX; + view all (2021) Systemic anti-cancer therapy and metastatic cancer are independent mortality risk factors during two uk waves of the covid-19 pandemic at university college london hospital. Cancers , 13 (23) , Article 6085. 10.3390/cancers13236085. Green open access
file

Wood, GE; Ledermann, JA; (2021) Adjuvant and post-surgical treatment in high-grade epithelial ovarian cancer. Best Practice & Research Clinical Obstetrics & Gynaecology 10.1016/j.bpobgyn.2021.09.002. (In press).

This list was generated on Mon May 23 00:04:18 2022 BST.